Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-26
2005-04-26
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S152000, C514S192000, C514S198000, C514S311000, C514S601000, C514S631000, C514S824000
Reexamination Certificate
active
06884784
ABSTRACT:
The present invention provides a unique approach for the diagnosis and management of infections byChlamydiaspecies, particularlyC. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.
REFERENCES:
patent: 5424187 (1995-06-01), Shor et al.
patent: 5935926 (1999-08-01), Scarborough et al.
patent: 6093743 (2000-07-01), Lai et al.
patent: 6258532 (2001-07-01), Stratton et al.
patent: 6432962 (2002-08-01), Hornemann
patent: 6565828 (2003-05-01), Liu
patent: 0 192033 (1986-08-01), None
patent: 0 337733 (1989-10-01), None
patent: 0 546761 (1993-06-01), None
patent: 0 699688 (1996-03-01), None
patent: 9850074 (1998-11-01), None
patent: WO 9220352 (1999-11-01), None
The Merck manual of Diagnosis and Therapy, 16thEd., pp. 181-182, 257-258 and 691-694 (1992).
Burchell, H.J., et al., “Efficacy of Different Antibiotics in the Treatment of Pelvic Inflammatory Disease”, SAMJ., 72: 248-249 (1987).
Henry-Suchet, J., “Traitement Des Infections Utero-Annexielles Sexuellement Transmises (IUAST) Sauf Syphillis Et Herpes”, Med. Mal. Infect., 24:379-387 (1994).
Heinonen, Pentti K., et al., “A Comparison of Ciprofloxacin with Doxycycline plus Metronidazole in the Treatment of Acute Pelvic Inflammatory Disease”, Scand. J. Infect. Dis. Suppl., 60: 66-73 (1989).
Joly-Guillou, M.L., et al., “Bacteries Isolees En 1994-1995 Au Cours Des Infections Gynecologiques Hautes Et Des Urethrites Masculines”, La Presse Medicate 2-9 Mars 25, (8): 342-348 (1996).
Judlin, P., et al., “Etude Comparative Des Associations Ofloxacine+Amoxicilline-Acide Clavulanique Versus Doxycycline+Amoxicilline-Acide Clavulanique Dans Le Traitement Des Infections Genitales Hautes A Chlamydia Trachomatis”. J. Gynecol. Obstet. Biol. Reprod. 24: 253-259 (1995).
Miettinen, A., et al., “The Effect of Ciprofloxacin and Doxycyline Plus Metronidazole on Lower Genital Tract Flora in Patients with Proven Pelvic Inflammatory Disease”, Arch. Gynecol. Obstet., 249: 95-101 (1991).
Orfila, J. and Haider, F., “Comparative Study of the In Vitro Activity of Lomefloxacin Versus Lomefloxacin Combined With Metronidazole Versus Lomefloxacin In Combination With Amoxicillin/Clavulanic Acid Against Chlamydia Trachomatis”, Intern. J. Antimicro. Agents, 2: 11-14 (1992).
Paavonen, J., et al., “Factors Predicting Abnormal Hysterosal-pingographic Findings in Patients Treated for Acute Pelvic Inflammatory Disease”, Int. J. Gynaecol. Obstet., 23: 171-175 (1985).
Witte, E.H., et al., “A Comparison of Pefloxacin/Metronidazole and Doxycyline/Metronidazole in the Treatment of Laparoscopically Confirmed Actue Pelvic Inflammatory Disease”, Eur. J. Obstet. Gynec. And Repro. Bio., 50: 153-158 (1993).
Wang et al., “Effects of Ascorbic Acid on Chlyamydia Trachomatis Infection and on Erythromycin Treatment in Primary Cultures of Human Amniotic Cells”, J. Clin. Microbiol., 30, 2551-2554.
Windholz et al., The Merck Index, Tenth Edition, 1983, pp. 531, 532, 1017 and 1187.
Budavari et al., The Merck Index, Twelfth Edition, 1996, p. 157.
Anderson et al., “The ACADEMIC Study in Perspective (Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia),”The Journal of Infectious Diseases181:S569-S571, (2000).
Anestad et al., “Chronic Infections and Coronary Heart Disease,”The Lancet350: 1028, (1997).
Boman et al., “Chlamydia pneumoniaeand Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies,”Clinical Microbiology Reviews15:1-20, (2002).
Campbell et al., “Chlamydia pneumoniaeand Atherosclerosis,”Seminars in Respiratory Infections18:48-54, (2003).
Dugan et al., “Review of Evidence for a Connection BetweenChlamydia pneumoniaeand Atheroscierotic Disease,”Clinical Therapeutics24:719-735, (2002).
Gabay et al., “Role of Antibiotics for the Prevention of Cardiovascular Disease,”The Annals of Pharmacotherapy36:1629-1636, (2002).
Gieffers et al., “Chlamydia pneumoniaeInfection In Circulating Human Monocytes Is Refractory to Antibiotic Treatment,”Circulation103:351-356, (2001).
Grayston, “Antibiotic Treatment of Atherosclerotic Cardiovascular Disease,”Circulation107:1228-1230, (2003).
Gupta et al., “ElevatedChlamydia pneumoniaeAntibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction,”Circulation96:404-407, (1997).
Gurfinkel et al., “Chlamydia pneumoniaein Coronary Artery Disease,”Circulation101:E118-119, (2002).
Gurfinkel et al., “Randomised Trial of Roxithromycin in Non-Q-wave Coronary Syndromes: ROXIS Pilot Study,”The Lancet350:404-407, (1997).
Halliwell et al., “Chronic Infections and Coronary Heart Disease,”The Lancet350:1030, (1997).
Harvard University Gazette “Chlamydia pneumoiaeMay Conribute to Stroke, Heart Attacks,” Dec. 12, 2002.
Higgins, “Chlamydia pneumoniaeand Coronary Artery Disease: The Antibiotic Trials,”Mayo Clin Prco. 78:321-332 (2003).
Hoymans et al., “Chlamydia pneumoniaeand Atherosclerosis,”Acta Chir Belg102:317-322, (2002).
Huittinen et al., “Synergistic Effect of PersistentChlamydia pneumoniaeInfection, Autoimmunity, and Inflammation on Coronary Risk,”Circulation107:2566-2570, (2003).
Lip et al., “Can We Treat Coronary Artery Disease With Antibiotics?,”The Lancet350:378-379, (1997).
Marchioli et al., “Chronic Infections and Coronary Heart Disease. The GISSI-Prevenzione Investigators,”The Lancet350:1028-1029, (1997).
Neumann, “Chlamydia pneumoniae-Atherosclerosis Link. A Sound Concept in Search for Clinical Relevance,”Circulation106:2414-2416, (2002).
Ngeh et al., “Chlamydia pneumoniaeand Atherosclerosis—What We Know and What We Don't,”Clin. Microbiol. Infect. 8:2-13, (2002).
Pislaru et al., “Antibiotic Therapy for Coronary Artery Disease. Can a WIZARD Change It All?,”JAMA290:1515-1516, (2003).
Ralayoglu et al., “Chlamydia pneumoniaeas an Emerging Risk Factor in Cardiovascular Disease,”JAMA288:2734-2731, (2002).
Sander et al., “Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment andChlamydia pneumoniaeSeropositivity”Circulation106:2428-2433, (2002).
SoRelle, “TreatingChlamydia pneumoniaein Patients With Early Atherosclerosis,”Circulation106:e9047, (2002).
Vaughnan et al., “Chronic Infections and Coronary Heart Disease,”The Lancet350:1029-1030, (1997).
Mitchell William M.
Stratton Charles W.
Clark & Elbing LLP
Vanderbilt University
Weddington Kevin E.
LandOfFree
Diagnosis and management of infection caused by chlamydia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and management of infection caused by chlamydia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and management of infection caused by chlamydia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403662